Denosumab Uptake Could Depend On Abating Physicians’ Financial Risk

If denosumab is approved, Amgen may need to provide physicians with a shield against the financial risk of stocking the injectable osteoporosis treatment in their offices

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet